Background: Lupus nephritis (LN) is still associated with significant mortality and substantial risk of progression to end-stage renal failure. Its outcome is related to the class and severity of LN and response to treatment, and it is poorer in patients with renal relapses. Ethnicity has a relatively well-defined impact on the outcome of the patients and their response to treatment and must always be taken into consideration in treatment decisions. Summary: In this article, we provide a review of the impact of ethnicity on the prevalence of systemic lupus erythematosus (SLE), the proportion of patients with SLE developing LN, outcomes of SLE and LN and response of LN to treatment. In European patients, the prevalence of SLE and the proportion of SLE patients with LN are lower and the outcome of LN is better than in nonwhite populations. European patients may respond better to some modes of treatment [e.g. cyclophosphamide (CYC) or rituximab] and may be less frequently refractory to treatment compared to black patients with LN. Although these differences may be largely genetically driven, socioeconomic factors (poverty, education, insurance, access to health care and adherence to treatment) may also play a significant role in some disadvantaged patients. Key Message: Treatment of LN may be different in patients with different ethnicity. Less aggressive disease in European patients may better respond to less aggressive treatment. Treatment of LN in nonwhite patients may require newer (more effective) therapeutic approaches, but targeting negative socioeconomic factors might be even more effective. Facts from East and West: (1) The prevalence of SLE is lower among Caucasians than other ethnicities. A higher prevalence is observed among Asians and African Americans, while the highest prevalence is found in Caribbean people. The prevalence of LN in Asian SLE patients is much higher than in Caucasians as well. However, the 10-year renal outcome and renal survival rate appear to be better in Asians. (2) Polymorphisms of genes involved in the immune response, such as Fcγ receptor, integrin alpha M, TNF superfamily 4, myotubularin-related protein 3 and many others, might be partly responsible for the differences in prevalence between the different ethnic groups. European ancestry was shown to be associated with a decrease in the risk of LN even after adjustment for genes most associated with renal disease. (3) Access to health care is a key determinant of disease progression, treatment outcome and the management of complications such as infections, particularly in South Asia, and might also explain disparities between clinical outcomes. (4) The efficacy of low-dose CYC combined with corticosteroids for induction treatment of LN was proved in European Caucasian patients. This treatment is also used in Asia, although no formal evaluation of efficacy and safety in comparison with other treatment regimens exists in this population. The efficacy of mycophenolate mofetil (MMF) is similar to that of CYC, and similar between Asians and Caucasians. MMF may be more effective than CYC in inducing response in high-risk populations such as African American or Hispanic patients. MMF might cause less infection-related events in Asians, but its high cost prevents broader usage at present. (5) For maintenance therapy, corticosteroid combined with azathioprine (AZA) or MMF is used worldwide, with a broadly similar efficacy of both treatments, although there are data suggesting that in high-risk populations (e.g. African Americans) MMF may be more effective in preventing renal flares. AZA is often preferred in Asia due to economic constraints and because of its safety in pregnancy. (6) Alternative therapies under investigation include rituximab, which might be more efficient in Caucasians, as well as belimumab. Recent Japanese and Chinese studies have indicated a potential benefit of tacrolimus as a substitute for or in addition to CYC or MMF (dual or triple immunosuppression). Mizoribine is used in Japan exclusively.

Keywords:
Lupus nephritis, Ethnicity, Prevalence, Outcome, Cyclophosphamide, Mycophenolate mofetil
1.
González LA, Toloza SM, Alarcón GS: Impact of race and ethnicity in the course and outcome of systemic lupus erythematosus. Rheum Dis Clin North Am 2014;40:433-454.
2.
Borchers AT, Naguwa SM, Shoenfeld Y, et al: The geoepidemiology of systemic lupus erythematosus. Autoimmun Rev 2010;9:A277-A287.
3.
Naleway AL, Davis ME, Greenlee RT, et al: Epidemiology of systemic lupus erythematosus in rural Wisconsin. Lupus 2005;14:862-866.
4.
Chakravarty EF, Bush TM, Manzi S, et al: Prevalence of adult systemic lupus erythematosus in California and Pennsylvania in 2000: estimates obtained using hospitalization data. Arthritis Rheum 2007;56:2092-2094.
5.
Hopkinson ND, Doherty M, Powell RJ: The prevalence and incidence of systemic lupus erythematosus in Nottingham, UK, 1989-1990. Br J Rheumatol 1993;32:110-115.
6.
Johnson AE, Gordon C, Palmer RG, et al: The prevalence and incidence of systemic lupus erythematosus in Birmingham, England. Relationship to ethnicity and country of birth. Arthritis Rheum 1995;38:551-558.
7.
Samanta A, Feehally J, Roy S, et al: High prevalence of systemic disease and mortality in Asian subjects with systemic lupus erythematosus. Ann Rheum Dis 1991;50:490-492.
8.
Pons-Estel GJ, Alarcón GS, Scofield L, et al: Understanding the epidemiology and progression of systemic lupus erythematosus. Semin Arthritis Rheum 2010;39:257-268.
9.
Rees F, Doherty M, Grainge M, et al: The incidence and prevalence of systemic lupus erythematosus in the UK, 1999-2012. Ann Rheum Dis 2014, DOI: 10.1136/annrheumdis- 2014-206334.
10.
Arnaud L, Fagot JP, Mathian A, et al: Prevalence and incidence of systemic lupus erythematosus in France: a 2010 nation-wide population-based study. Autoimmun Rev 2014;13:1082-1089.
11.
Alarcón GS, McGwin G Jr, Petri M, et al: Baseline characteristics of a multiethnic lupus cohort: PROFILE. Lupus 2002;11:95-101.
12.
Pons-Estel BA, Catoggio LJ, Cardiel MH, et al: The GLADEL multinational Latin American prospective inception cohort of 1,214 patients with systemic lupus erythematosus: ethnic and disease heterogeneity among ‘Hispanics'. Medicine (Baltimore) 2004;83:1-17.
13.
Ward MM, Pyun E, Studenski S: Long-term survival in systemic lupus erythematosus. Patient characteristics associated with poorer outcome. Arthritis Rheum 1995;38:274-283.
14.
Wang F, Wang CL, Tan CT, et al: Systemic lupus erythematosus in Malaysia: a study of 539 patients and comparison of prevalence and disease expression in different racial and gender groups. Lupus 1997;6:248-253.
15.
Mok CC, To CH, Ho LY, et al: Incidence and mortality of systemic lupus erythematosus in a southern Chinese population, 2000-2006. J Rheumatol 2008;35:1978-1982.
16.
Malaviya AN, Chandrasekaran AN, Kumar A, et al: Systemic lupus erythematosus in India. Lupus 1997;6:690-700.
17.
Cervera R, Khamashta MA, Font J, et al: Morbidity and mortality in systemic lupus erythematosus during a 5-year period. A multicenter prospective study of 1,000 patients. European Working Party on Systemic Lupus Erythematosus. Medicine (Baltimore) 1999;78:167-175.
18.
Cervera R, Abarca-Costalago M, Abramovicz D, et al: Systemic lupus erythematosus in Europe at the change of the millennium: lessons from the ‘Euro-Lupus Project'. Autoimmun Rev 2006;5:180-186.
19.
Patel M, Clarke AM, Bruce IN, et al: The prevalence and incidence of biopsy-proven lupus nephritis in the UK: evidence of an ethnic gradient. Arthritis Rheum 2006;54:2963-2969.
20.
Ramos PS, Shaftman SR, Ward RC, et al: Genes associated with SLE are targets of recent positive selection. Autoimmune Dis 2014;2014:203435.
21.
Moser KL, Kelly JA, Lessard CJ, et al: Recent insights into the genetic basis of systemic lupus erythematosus. Genes Immun 2009;10:373-379.
22.
Chung SA, Brown EE, Williams AH, et al: Lupus nephritis susceptibility loci in women with systemic lupus erythematosus. J Am Soc Nephrol 2014;25:2859-2870.
23.
Manku H, Langefeld CD, Guerra SG, et al: Trans-ancestral studies fine map the SLE-susceptibility locus TNFSF4. PLoS Genet 2013;9:e1003554.
24.
Namjou B, Kim-Howard X, Sun C, et al: PTPN22 association in systemic lupus erythematosus (SLE) with respect to individual ancestry and clinical sub-phenotypes. PLoS One 2013;8:e69404.
25.
Lin CP, Adrianto I, Lessard CJ, et al: Role of MYH9 and APOL1 in African and non-African populations with lupus nephritis. Genes Immun 2012;13:232-238.
26.
Lee HS, Bae SC: What can we learn from genetic studies of systemic lupus erythematosus? Implications of genetic heterogeneity among populations in SLE. Lupus 2010;19:1452-1459.
27.
Gibbons A: Human evolution. Neandertals and moderns made imperfect mates. Science 2014;343:471-472.
28.
Richman IB, Taylor KE, Chung SA, et al: European genetic ancestry is associated with a decreased risk of lupus nephritis. Arthritis Rheum 2012;64:3374-3382.
29.
Alarcón GS, Bastian HM, Beasley TM, et al: Systemic lupus erythematosus in a multi-ethnic cohort (LUMINA XXXII): contributions of admixture and socioeconomic status to renal involvement. Lupus 2006;15:26-31.
30.
Coit P, Jeffries M, Altorok N, et al: Genome-wide DNA methylation study suggests epigenetic accessibility and transcriptional poising of interferon-regulated genes in naive CD4+ T cells from lupus patients. J Autoimmun 2013;43:78-84.
31.
Coit P, Renauer P, Jeffries MA, et al: Renal involvement in lupus is characterized by unique DNA methylation changes in naïve CD4+ T cells. J Autoimmun 2015;61:29-35.
32.
Danila MI, Pons-Estel GJ, Zhang J, et al: Renal damage is the most important predictor of mortality within the damage index: data from LUMINA LXIV, a multiethnic cohort. Rheumatology (Oxford) 2009;48:542-545.
33.
Gómez-Puerta JA, Barbhaiya M, Guan H, et al: Racial/ethnic variation in all-cause mortality among United States Medicaid recipients with systemic lupus erythematosus: a Hispanic and Asian paradox. Arthritis Rheumatol 2015;67:752-760.
34.
Vasudevan A, Krishnamurthy AN: Changing worldwide epidemiology of systemic lupus erythematosus. Rheum Dis Clin North Am 2010;36:1-13.
35.
González LA, Toloza SM, McGwin G Jr, et al: Ethnicity in systemic lupus erythematosus (SLE): its influence on susceptibility and outcomes. Lupus 2013;22:1214-1224.
36.
Colares VS, Titan SM, Pereira Ada C, et al: MYH9 and APOL1 gene polymorphisms and the risk of CKD in patients with lupus nephritis from an admixture population. PLoS One 2014;9:e87716.
37.
Freedman BI, Langefeld CD, Andringa KK, et al: End-stage renal disease in African Americans with lupus nephritis is associated with APOL1. Arthritis Rheumatol 2014;66:390-396.
38.
Eilertsen GO, Fismen S, Hanssen TA, et al: Decreased incidence of lupus nephritis in northern Norway is linked to increased use of antihypertensive and anticoagulant therapy. Nephrol Dial Transplant 2011;26:620-627.
39.
Contreras G, Lenz O, Pardo V, et al: Outcomes in African Americans and Hispanics with lupus nephritis. Kidney Int 2006;69:1846-1851.
40.
Cervera R, Doria A, Amoura Z, et al: Patterns of systemic lupus erythematosus expression in Europe. Autoimmun Rev 2014;13:621-629.
41.
Watson P, Brennan A, Birch H, et al: An integrated extrapolation of long-term outcomes in systemic lupus erythematosus: analysis and simulation of the Hopkins lupus cohort. Rheumatology (Oxford) 2015;54:623-632.
42.
Golder V, Connelly K, Staples M, et al: Association of Asian ethnicity with disease activity in SLE: an observational study from the Monash Lupus Clinic. Lupus 2013;22:1425-1430.
43.
Stratta P, Mesiano P, Campo A, et al: Life expectancy of women with lupus nephritis now approaches that of general population. Int J Immunopathol Pharmacol 2009;22:1135-1141.
44.
Croca SC, Rodrigues T, Isenberg DA: Assessment of a lupus nephritis cohort over a 30-year period. Rheumatology (Oxford) 2011;50:1424-1430.
45.
Hui M, Garner R, Rees F, et al: Lupus nephritis: a 15-year multi-centre experience in the UK. Lupus 2013;22:328-332.
46.
Barr RG, Seliger S, Appel GB, et al: Prognosis in proliferative lupus nephritis: the role of socioeconomic status and race/ethnicity. Nephrol Dial Transplant 2003;18:2039-2046.
47.
Korbet SM, Schwartz MM, Evans J, et al: Severe lupus nephritis: racial differences in presentation and outcome. J Am Soc Nephrol 2007;18:244-254.
48.
Austin HA 3rd, Boumpas DT, Vaughan EM, et al: High-risk features of lupus nephritis: importance of race and histological factors in 166 patients. Nephrol Dial Transplant 1995;10:1620-1628.
49.
Kuan WP, Li EK, Tam LS: Lupus organ damage: what is damaged in Asian patients? Lupus 2010;19:1436-1441.
50.
Mok MY, Li WL: Do Asian patients have worse lupus? Lupus 2010;19:1384-1390.
51.
Ong C, Nicholls K, Becker G: Ethnicity and lupus nephritis: an Australian single centre study. Intern Med J 2011;41:270-278.
52.
Moroni G, Quaglini S, Gallelli B, et al: The long-term outcome of 93 patients with proliferative lupus nephritis. Nephrol Dial Transplant 2007;22:2531-2539.
53.
Chan TM, Tse KC, Tang CS, et al: Long-term outcome of patients with diffuse proliferative lupus nephritis treated with prednisolone and oral cyclophosphamide followed by azathioprine. Lupus 2005;14:265-272.
54.
Plantinga LC, Drenkard C, Patzer RE, et al: Sociodemographic and geographic predictors of quality of care in United States patients with end-stage renal disease due to lupus nephritis. Arthritis Rheumatol 2015;67:761-772.
55.
Costenbader KH, Desai A, Alarcón GS, et al: Trends in the incidence, demographics and outcomes of end-stage renal disease due to lupus nephritis in the US from 1995 to 2006. Arthritis Rheumatol 2011;63:1681-1688.
56.
Gómez-Puerta JA, Feldman CH, Alarcón GS, et al: Racial and ethnic differences in mortality and cardiovascular events among patients with end-stage renal disease due to lupus nephritis. Arthritis Care Res (Hoboken) 2015, DOI: 10.1002/acr.22562.
57.
Nee R, Jindal RM, Little D, et al: Racial differences and income disparities are associated with poor outcomes in kidney transplant recipients with lupus nephritis. Transplantation 2013;95:1471-1478.
58.
Contreras G, Mattiazzi A, Guerra G, et al: Recurrence of lupus nephritis after kidney transplantation. J Am Soc Nephrol 2010;21:1200-1207.
59.
Contreras G, Mattiazzi A, Schultz DR, et al: Kidney transplantation outcomes in African-, Hispanic- and Caucasian-Americans with lupus. Lupus 2012;21:3-12.
60.
Contreras G, Li H, Gonzalez-Suarez M, et al: Kidney allograft survival of African American and Caucasian American recipients with lupus. Lupus 2014;23:151-158.
61.
Austin HA 3rd, Klippel JH, Balow JE, et al: Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med 1986;314:614-619.
62.
Gourley MF, Austin HA 3rd, Scott D, et al: Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized controlled trial. Ann Intern Med 1996;125:549-557.
63.
Houssiau FA, Vasconselos C, D'Cruz D, et al: Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 2002;46:2121-2131.
64.
Houssiau FA, Vasconcelos C, D'Cruz D, et al: The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide. Ann Rheum Dis 2010;69:61-64.
65.
Yap DY, Chan TM: Treatment of lupus nephritis: practical issues in Asian countries. Int J Rheum Dis 2015;18:135-145.
66.
The ACCESS Trial Group: Treatment of lupus nephritis with abatacept: the abatacept and cyclophosphamide combination efficacy and safety study. Arthritis Rheumatol 2014;66:3096-3104.
67.
Appel GB, Contreras G, Dooley MA, et al: Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 2009;20:1103-1112.
68.
Rovin BH, Furie R, Latinis K, et al: Efficacy and safety or rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum 2012;64:1215-1226.
69.
Wofsy D, Diamond B, Houssiau FA: Crossing the Atlantic: the Euro-Lupus Nephritis regimen in North America. Arthritis Rheumatol 2015;67:1144-1146.
70.
Isenberg D, Appel GB, Contreras G, et al: Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study. Rheumatology (Oxford) 2010;49:128-140.
71.
Dall'Era M, Levesque V, Solomons N, et al: Identification of clinical and serological factors during induction treatment of lupus nephritis that are associated with renal outcome. Lupus Sci Med 2015;2:e000089.
72.
Dooley MA, Jayne D, Ginzler E, et al: Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med 2011;365:1886-1895.
73.
Houssiau FA, D'Cruz D, Sangle S, et al: Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial. Ann Rheum Dis 2010;69:2093-2089.
74.
Stoenoiu MS, Aydin S, Tektonidou M, et al: Repeat kidney biopsies fail to detect differences between azathioprine and mycophenolate mofetil maintenance therapy for lupus nephritis: data from the MAINTAIN Nephritis Trial. Nephrol Dial Transplant 2012;27:1924-1930.
75.
Tamirou F, D'Cruz D, Sangle S, et al: Long-term follow-up of the MAINTAIN Nephritis Trial, comparing azathioprine and mycophenolate mofetil as maintenance therapy of lupus nephritis. Ann Rheum Dis 2015, DOI: 10.1136/annrheumdis-2014-206897.
76.
Tesar V, Hruskova Z: Treatment of proliferative lupus nephritis: a slowly changing landscape. Nat Rev Nephrol 2011;7:96-109.
77.
Pons-Estel GJ, Serrano R, Plasín MA, et al: Epidemiology and management of refractory lupus nephritis. Autoimmun Rev 2011;10:655-663.
78.
Melander C, Sallée M, Trolliet P, et al: Rituximab in severe lupus nephritis: early B-cell depletion affects long-term renal outcome. Clin J Am Soc Nephrol 2009;4:579-587.
79.
Ramos-Casals M, Diaz-Lagares C, Soto-Cardenas MJ, et al: Rituximab therapy in lupus nephritis: current clinical evidence. Clin Rev Allergy Immunol 2011;40:159-169.
80.
Díaz-Lagares C, Croca S, Sangle S, et al: Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: pooled data from European cohorts. Autoimmun Rev 2012;11:357-364.
81.
Vina ER, Masi CM, Green SL, et al: A study of racial/ethnic differences in treatment preferences among lupus patients. Rheumatology (Oxford) 2012;51:1697-1706.
82.
Vina ER, Utset TO, Hannon MJ, et al: Racial differences in the treatment preferences among lupus patients: a two site study. Clin Exp Rheumatol 2014;32:680-688.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.